An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011

John B. Eifler, Zhaoyang Feng, Brian M. Lin, Michael T. Partin, Elizabeth B. Humphreys, Misop Han, Jonathan Ira Epstein, Patrick Walsh, Bruce Trock, Alan Wayne Partin

Research output: Contribution to journalArticle

Abstract

Objective: To update the 2007 Partin tables in a contemporary patient population. Patients and Methods: The study population consisted of 5,629 consecutive men who underwent RP and staging lymphadenectomy at the Johns Hopkins Hospital between January 1, 2006 and July 30, 2011 and met inclusion criteria. Polychotomous logistic regression analysis was used to predict the probability of each pathologic stage category: organ-confined disease (OC), extraprostatic extension (EPE), seminal vesicle involvement (SV+), or lymph node involvement (LN+) based on preoperative criteria. Preoperative variables included biopsy Gleason score (6, 3+4, 4+3, 8, and 9-10), serum PSA (0-2.5, 2.6-4.0, 4.1-6.0, 6.1-10.0, greater than 10.0 ng/mL), and clinical stage (T1c, T2c, and T2b/T2c). Bootstrap re-sampling with 1000 replications was performed to estimate 95% confidence intervals for predicted probabilities of each pathologic state. Results The median PSA was 4.9 ng/mL, 63% had Gleason 6 disease, and 78% of men had T1c disease. 73% of patients had OC disease, 23% had EPE, 3% had SV+ but not LN+, and 1% had LN+ disease. Compared to the previous Partin nomogram, there was no change in the distribution of pathologic state. The risk of LN+ disease was significantly higher for tumours with biopsy Gleason 9-10 than Gleason 8 (O.R. 3.2, 95% CI 1.3-7.6). The c-indexes for EPE vs. OC, SV+ vs. OC, and LN+ vs. OC were 0.702, 0.853, and 0.917, respectively. Men with biopsy Gleason 4+3 and Gleason 8 had similar predicted probabilities for all pathologic stages. Most men presenting with Gleason 6 disease or Gleason 3+4 disease have

Original languageEnglish (US)
Pages (from-to)22-29
Number of pages8
JournalBJU International
Volume111
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Nomograms
Neoplasm Staging
Prostatic Neoplasms
Biopsy
Neoplasm Grading
Seminal Vesicles
Lymph Node Excision
Population
Logistic Models
Lymph Nodes

Keywords

  • nomograms
  • prostage-specific antigen
  • prostate cancer
  • prostatectomy
  • staging

ASJC Scopus subject areas

  • Urology

Cite this

An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. / Eifler, John B.; Feng, Zhaoyang; Lin, Brian M.; Partin, Michael T.; Humphreys, Elizabeth B.; Han, Misop; Epstein, Jonathan Ira; Walsh, Patrick; Trock, Bruce; Partin, Alan Wayne.

In: BJU International, Vol. 111, No. 1, 01.2013, p. 22-29.

Research output: Contribution to journalArticle

Eifler, John B. ; Feng, Zhaoyang ; Lin, Brian M. ; Partin, Michael T. ; Humphreys, Elizabeth B. ; Han, Misop ; Epstein, Jonathan Ira ; Walsh, Patrick ; Trock, Bruce ; Partin, Alan Wayne. / An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. In: BJU International. 2013 ; Vol. 111, No. 1. pp. 22-29.
@article{db86125fed264da4850ad610757e88ba,
title = "An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011",
abstract = "Objective: To update the 2007 Partin tables in a contemporary patient population. Patients and Methods: The study population consisted of 5,629 consecutive men who underwent RP and staging lymphadenectomy at the Johns Hopkins Hospital between January 1, 2006 and July 30, 2011 and met inclusion criteria. Polychotomous logistic regression analysis was used to predict the probability of each pathologic stage category: organ-confined disease (OC), extraprostatic extension (EPE), seminal vesicle involvement (SV+), or lymph node involvement (LN+) based on preoperative criteria. Preoperative variables included biopsy Gleason score (6, 3+4, 4+3, 8, and 9-10), serum PSA (0-2.5, 2.6-4.0, 4.1-6.0, 6.1-10.0, greater than 10.0 ng/mL), and clinical stage (T1c, T2c, and T2b/T2c). Bootstrap re-sampling with 1000 replications was performed to estimate 95{\%} confidence intervals for predicted probabilities of each pathologic state. Results The median PSA was 4.9 ng/mL, 63{\%} had Gleason 6 disease, and 78{\%} of men had T1c disease. 73{\%} of patients had OC disease, 23{\%} had EPE, 3{\%} had SV+ but not LN+, and 1{\%} had LN+ disease. Compared to the previous Partin nomogram, there was no change in the distribution of pathologic state. The risk of LN+ disease was significantly higher for tumours with biopsy Gleason 9-10 than Gleason 8 (O.R. 3.2, 95{\%} CI 1.3-7.6). The c-indexes for EPE vs. OC, SV+ vs. OC, and LN+ vs. OC were 0.702, 0.853, and 0.917, respectively. Men with biopsy Gleason 4+3 and Gleason 8 had similar predicted probabilities for all pathologic stages. Most men presenting with Gleason 6 disease or Gleason 3+4 disease have",
keywords = "nomograms, prostage-specific antigen, prostate cancer, prostatectomy, staging",
author = "Eifler, {John B.} and Zhaoyang Feng and Lin, {Brian M.} and Partin, {Michael T.} and Humphreys, {Elizabeth B.} and Misop Han and Epstein, {Jonathan Ira} and Patrick Walsh and Bruce Trock and Partin, {Alan Wayne}",
year = "2013",
month = "1",
doi = "10.1111/j.1464-410X.2012.11324.x",
language = "English (US)",
volume = "111",
pages = "22--29",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011

AU - Eifler, John B.

AU - Feng, Zhaoyang

AU - Lin, Brian M.

AU - Partin, Michael T.

AU - Humphreys, Elizabeth B.

AU - Han, Misop

AU - Epstein, Jonathan Ira

AU - Walsh, Patrick

AU - Trock, Bruce

AU - Partin, Alan Wayne

PY - 2013/1

Y1 - 2013/1

N2 - Objective: To update the 2007 Partin tables in a contemporary patient population. Patients and Methods: The study population consisted of 5,629 consecutive men who underwent RP and staging lymphadenectomy at the Johns Hopkins Hospital between January 1, 2006 and July 30, 2011 and met inclusion criteria. Polychotomous logistic regression analysis was used to predict the probability of each pathologic stage category: organ-confined disease (OC), extraprostatic extension (EPE), seminal vesicle involvement (SV+), or lymph node involvement (LN+) based on preoperative criteria. Preoperative variables included biopsy Gleason score (6, 3+4, 4+3, 8, and 9-10), serum PSA (0-2.5, 2.6-4.0, 4.1-6.0, 6.1-10.0, greater than 10.0 ng/mL), and clinical stage (T1c, T2c, and T2b/T2c). Bootstrap re-sampling with 1000 replications was performed to estimate 95% confidence intervals for predicted probabilities of each pathologic state. Results The median PSA was 4.9 ng/mL, 63% had Gleason 6 disease, and 78% of men had T1c disease. 73% of patients had OC disease, 23% had EPE, 3% had SV+ but not LN+, and 1% had LN+ disease. Compared to the previous Partin nomogram, there was no change in the distribution of pathologic state. The risk of LN+ disease was significantly higher for tumours with biopsy Gleason 9-10 than Gleason 8 (O.R. 3.2, 95% CI 1.3-7.6). The c-indexes for EPE vs. OC, SV+ vs. OC, and LN+ vs. OC were 0.702, 0.853, and 0.917, respectively. Men with biopsy Gleason 4+3 and Gleason 8 had similar predicted probabilities for all pathologic stages. Most men presenting with Gleason 6 disease or Gleason 3+4 disease have

AB - Objective: To update the 2007 Partin tables in a contemporary patient population. Patients and Methods: The study population consisted of 5,629 consecutive men who underwent RP and staging lymphadenectomy at the Johns Hopkins Hospital between January 1, 2006 and July 30, 2011 and met inclusion criteria. Polychotomous logistic regression analysis was used to predict the probability of each pathologic stage category: organ-confined disease (OC), extraprostatic extension (EPE), seminal vesicle involvement (SV+), or lymph node involvement (LN+) based on preoperative criteria. Preoperative variables included biopsy Gleason score (6, 3+4, 4+3, 8, and 9-10), serum PSA (0-2.5, 2.6-4.0, 4.1-6.0, 6.1-10.0, greater than 10.0 ng/mL), and clinical stage (T1c, T2c, and T2b/T2c). Bootstrap re-sampling with 1000 replications was performed to estimate 95% confidence intervals for predicted probabilities of each pathologic state. Results The median PSA was 4.9 ng/mL, 63% had Gleason 6 disease, and 78% of men had T1c disease. 73% of patients had OC disease, 23% had EPE, 3% had SV+ but not LN+, and 1% had LN+ disease. Compared to the previous Partin nomogram, there was no change in the distribution of pathologic state. The risk of LN+ disease was significantly higher for tumours with biopsy Gleason 9-10 than Gleason 8 (O.R. 3.2, 95% CI 1.3-7.6). The c-indexes for EPE vs. OC, SV+ vs. OC, and LN+ vs. OC were 0.702, 0.853, and 0.917, respectively. Men with biopsy Gleason 4+3 and Gleason 8 had similar predicted probabilities for all pathologic stages. Most men presenting with Gleason 6 disease or Gleason 3+4 disease have

KW - nomograms

KW - prostage-specific antigen

KW - prostate cancer

KW - prostatectomy

KW - staging

UR - http://www.scopus.com/inward/record.url?scp=84871573421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871573421&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2012.11324.x

DO - 10.1111/j.1464-410X.2012.11324.x

M3 - Article

C2 - 22834909

AN - SCOPUS:84871573421

VL - 111

SP - 22

EP - 29

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 1

ER -